3/85.0 for palmitoylcarnitine and m/z 176.1/134.2 for debrisoquine. Using Analyst software (Applied Biosystems), serum palmitoylcarnitine concentrations were determined by calculating the ratio between the peak area of palmitoylcarnitine and

the peak area of debrisoquine and fitting with a calibration curve with a linear range from 10 nM to 1 μM (r = 0.99). Statistical analysis was performed using GraphPad Prism (San Diego, CA). Analysis of variance (ANOVA) with Bonferroni’s multiple comparison test was used to compare the various groups. P < 0.05 was considered significant. Treatment of wildtype Talazoparib order mice with APAP for 6 hours results in massive hepatic toxicity as revealed by gross morphology of the liver (Fig. 1A), increased ALT and AST enzyme levels

(Fig. 1B), and faint pericentral and periportal H&E staining of liver parenchyma (Fig. 1C). Pretreatment with Wy-14,643 for 24 hours before APAP treatment results in total protection against APAP toxicity; Wy-14,643 treated mice had no evidence of liver damage. At 24 hours post-APAP treatment, Wy-14,643-treated mice were still protected, as indicated by reduced ALT enzyme levels and normal liver histology (Supporting Fig. 1). In contrast, Ppara-null mice exhibited no Wy-14,643 protection against APAP toxicity (shown by increased ALT and AST activities), indicating selleck products that the protection was PPARα-dependent (Fig. 2A). To demonstrate that the effect was not specific to the experimental ligand Wy-14,643 and to mouse PPARα, PPARα-humanized mice (a human PPARα gene introduced in the Ppara-null background) treated C-X-C chemokine receptor type 7 (CXCR-7) with fenofibrate were also protected (Fig. 2B). However, mice treated with the anti-Fas antibody Jo-2 to stimulate Fas receptor-mediated apoptosis were not protected from Wy-14,643 pretreatment (Supporting Fig. 2). Pretreatment

with Wy-14,643 did not significantly impact APAP metabolism, as demonstrated by serum profiling of APAP and its metabolites (APAP-NAC, APAP-glucuronide, APAP-CYS) 2 hours after APAP administration (Supporting Fig. 3). In order to understand the transcriptional responses associated with toxic doses of APAP-treatment and potential targets whereby PPARα was mediating its protective affects, microarray analysis was carried out on liver mRNA from 6 hours APAP-treated and Wy-14,643-pretreated/APAP-treated mice. A total of 53 genes were up-regulated by APAP and 45 genes up-regulated by Wy-14,643 /APAP; 14 genes were up-regulated by both treatments (greater than 10-fold). Most interesting was the marked induction and suppression of c-fos and c-jun expression upon APAP treatment and Wy-14,643-pretreatment prior to APAP administration, respectively (Fig. 3A). qPCR analysis confirmed that c-fos and c-jun mRNAs were robustly induced by APAP and suppressed by Wy-14,643-pretreatment prior to APAP (Fig. 3B).